Has Kaylene Carter, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,826 in general payments to Kaylene Carter, MD across 37 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Kaylene Carter, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Kaylene Carter, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Kaylene Carter, MD

Internal Medicine · West Reading, PANPI 1063037141

Payments from drug & device makers

$1,826in general payments, 2019–2025

Across 37 payments — averaging $49.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Alcon$709
Glaukos Corporation$240
Bausch & Lomb Americas Inc.$200
Johnson & Johnson Surgical Vision, Inc.$195
Biotissue Holdings Inc.$121
Pulmonx Corporation$83
plus $279 from 8 others

What the payments were for

Food & beverage$1,826100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Alcon	12	$709
Glaukos Corporation	2	$240
Bausch & Lomb Americas Inc.	6	$200
Johnson & Johnson Surgical Vision, Inc.	3	$195
Biotissue Holdings Inc.	1	$121
Pulmonx Corporation	1	$83
AbbVie	4	$75
Merz Pharmaceuticals, LLC	1	$52
Tarsus Pharmaceuticals, Inc.	2	$45
Oyster Point Pharma, Inc.	1	$31
Carl Zeiss Meditec USA, Inc.	1	$26
Sun Pharmaceutical Industries Inc.	1	$19
Stryker	1	$16
Sight Sciences, Inc.	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,826 in reported general payments places this provider in the 80th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$46,057

Medicare patients

154

Services billed

425

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Prednisolone Acetate	115	$3,900
Difluprednate	13	$1,701
Ketorolac Tromethamine	81	$1,183
MoxifloxacinMoxifloxacin Hcl	37	$1,002
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat	34	$899
Ofloxacin	46	$769
Acetazolamide	11	$541
ErythromycinErythromycin Base	46	$503
Latanoprost	53	$425
Dorzolamide Hcl	15	$281
Brimonidine Tartrate	29	$165

Paid to pharmacies, not to this prescriber.